4:23 PM
 | 
Feb 13, 2018
 |  BC Extra  |  Clinical News

Kadmon falls after Phase II IPF data

Kadmon Holdings Inc. (NYSE:KDMN) fell $1.03 (21%) to $3.81 on Tuesday after reporting top-line data from the Phase II KD025-207 trial of KD025 to treat idiopathic pulmonary fibrosis in patients previously treated with or offered Esbriet pirfenidone or Ofev nintedanib.

The company did not disclose p-values from the open-label trial, which may have left investors uncertain as to how the compound will stack up against marketed...

Read the full 307 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >